Autoimmune myasthenia gravis (MG) occurs in children, as well as in adults. Childhood myasthenia gravis is characterized by its distinct clinical features. Epidemiological studies have shown the high frequency of onset before the age of 5 years in Japan. Similar results have been reported from China. Clinical types are divided into pure ocular, latent generalized and generalized. In general, childhood myasthenia gravis is milder, mainly with ocular symptoms. Anti-acetylcholine receptor antibody is often negative (seronegative). The responsiveness to treatment is generally good, and almost 90% of patients can achieve complete remission. Early diagnosis and adequate treatments are important.
Introduction
Myasthenia gravis (MG) is an autoimmune disorder against the nicotinic acetylcholine receptor (AChR) at the postsynaptic membrane of the neuromuscular junction of skeletal muscle, leading clinically to muscle weakness and fatigability. It is known that MG occurs in young adults, but it also occurs in childhood. It is known as childhood MG or juvenile MG. Autoimmune MG in children is basically the same as in adult MG, but there are distinct and characteristic clinical features of childhood MG.
Historically, MG in children has been described since the 1950s, and in Japan the unique age distributions of the onset of MG have been noted since the 1960s; that is, the two peaks, with the highest in childhood, particularly <3 years-of-age. 1 Repeated nationwide epidemiological studies have shown the same high frequency of childhood MG in Japan. [2] [3] [4] [5] We have been involved in the medical care and study of childhood MG for almost 50 years. Our data and the reports from other ethnic groups are reviewed, and are discussed regarding the "issues and challenges" of childhood MG.
Epidemiology
The high incidence of childhood MG was noted in the 1960s (Fukuyama and Segawa) in Japan, 1 and the first nationwide study was carried out in 1973. 2 The total number of MG patients was 1430. The onset before 5 years-of-age was 14.7%, which formed the highest peak, and the onset between 5 and 10 yearsof-age was 6.8%. A study in 1987 4 showed the onset before 5 years-of-age was 10.1% among a total of 6000 patients, and a study carried out in 2006 5 showed the onset before 5 years was 7.0% among a total of 15 100 patients. Thus, the high peak of the onset before 5 years-of-age has remained the same for 33 years in Japan, although there has been a gradual decline from 14.7% to 10.1% to 7.0%. In contrast, the age of onset in adult patients is shifting to older.
High frequencies of childhood MG have also been reported from China. 6, 7 Among Chinese, 43% of patients manifest the disease before the age of 20 years. Different from the high frequency of childhood MG in Asia, it is not common among Caucasians, with pre-pubertal onset at <10%. In North America, onset of autoimmune MG before the age of 20 years accounts for approximately 10-20% of all patients with MG. 8, 9 The data from North Carolina, USA, showed that the incidence of juvenile MG in the prepubertal age group was approximately threefold higher in the black than in the white population. 10 These ethnic-based differences of the incidences of childhood MG might indicate that the genetic or predisposing backgrounds are playing important roles in the pathophysiology of childhood MG.
Clinical types
Previously, Osserman's classification was used to classify MG, where in addition to the ocular, bulbar and general type, childhood onset was classified as the juvenile type. Nowadays, Myasthenia Gravis Foundation of America classification is commonly used based on the severity of the disease. In Japan, clinical types of childhood-onset MG are divided into the pure ocular, latent general and general (including bulbar) type based on clinical and electrophysiological evaluation. 11 This classification is useful to decide the treatments and to predict the prognosis. 12 The latent general type was defined by Segawa in 1973 to describe patients with solely clinically ocular symptoms where electrophysiological examinations show the presence of decrement in extremity muscles. 11 Segawa noticed that the ratio of the number of ocular type MG against the number of general type MG reverses in childhood against adult-onset patients. It was also noticed that some ocular patients resist treatment and relapse. Based on this classification, the ratio of pure ocular against the addition of the latent general and general type comes to be equal to the ratio of the ocular type and general type in adult-onset MG patients.
Clinical features
Age of onset The age of onset was evaluated in 184 patients who attended the Segawa Neurological Clinic for Children, Tokyo, Japan, for 30 years from its foundation in 1973. 13 The age of onset of these patients was divided into five groups (I, II, III, IV and V), which show the gradual decline in frequency (Fig. 1) .
The five groups are:
1 Group I: onset <3 years-of-age 2 Group II: onset from 3 years to <6 years 3 Group III: onset from 6 years to <11 years 4 Group IV: onset from 11 years to <15 years 5 Group V; Onset from 15 years to <18 years
The clinical features, treatment and prognosis seem to be distinct in each group.
Sex
A total of 70% of all patients were female. However, no sex difference was observed in group II.
Clinical types
The clinical types of all 184 patients showed that 34 patients (18.5%) were the pure ocular type, 94 patients (51.1%) were the latent general type and 56 patients (30.4%) were the general type (Fig. 1) . The clinical type of the five groups showed that the ocular type accounted for 12-17%, except in the group III, which was 31%. The latent general type was the major type in group I and II (51 and 73%, respectively), but less in groups III and IV (38 and 35%, respectively). The general type was seen the Figure 1 Age of onset and clinical type. In total, 70% were female, particularly in patients whose onset age was <3 years. In patients with onset age of 3-6 years, there were no sex differences. Numbers in the column indicates the percentage against the total patients. least in group II (13%), whereas approximately 30% in group I and III, and 53% of group IV. The numbers of group V were small (4), but 75% were the general type.
Mode of onset
The mode of onset is insidious or might follow a non-specific viral infection, such as an upper respiratory infection. 14 
Symptoms
Childhood-onset MG is milder, mainly with ocular symptoms, in contrast with adult-onset MG. The Japanese nationwide study of 2006 showed that 80.6% of patients with onset at <5 years-of-age, and 61.5% of patients with onset at 5-10 years-of-age were Myasthenia Gravis Foundation of America class I. These were in contrast with 26.4% of patients with onset at 10-49 years-of-age. 5 The most frequent initial symptom is blepharoptosis with asymmetry. Other ocular symptoms, such as abnormality of extraocular movements and strabismus, might follow. Older children complain of double vision, and younger children, who are not able to verbalize, might present with tilting their head to correct the eye positions to avoid the diplopia. Some complain of photophobia, which is due to pupillary sphincter muscle involvement. 14 When the ptosis lasts a long time, the eyebrow of the prominent ptosis side is elevated and the wrinkles of the forehead become more prominent. These reflect that the child is trying to correct ptosis by using other muscles. When ptosis covers more than half of the pupil of one side, particularly before 3 years-of-age, amblyopia might develop. Regarding strabismus, lasting exotropia, not esotropia, might cause amblyopia. [14] [15] [16] [17] [18] This is because the child tends not to use the externally located eye.
Facial muscle weakness is observed often. Closing eyes are weak, and that is one of the frequently observed symptoms because of facial muscle weakness. Bulbar signs may present with vocalization abnormality and swallowing difficulty.
General symptoms are sometimes difficult to evaluate in younger children. When a child wants to be held, it might be the sign of general weakness. In the general type, weakness of general muscles and bulbar muscles might appear as the initial symptoms, but often appear within 0.5-1 years after the onset of ocular symptoms. When the age of onset was compared with the age of developing general symptoms, the earlier-onset patients developed general symptoms earlier; that is, group I at 5.3 months, group II at 1.6 months, group III at 2.5 months, group IV at 0.8 months and group V at 3.5 months (Yoshiko Nomura, unpubl. data).
During the course, the affected side changes or fluctuates. 14, 19 These symptoms usually show diurnal fluctuation, but might change during the treatment. Viral infections often aggravate the symptoms, but measles infection improves MG transiently or might bring about complete remission. Chicken pox and rubella infection can also show a similar effect, but it is not so marked as with measles infection. 14 It is known that other autoimmune diseases might occur with MG, such as thyroid dysfunction, either hyper or hypo. Bronchial asthma or other allergic disorders can also occur.
Familial occurrences of MG are high in childhood MG. We have seen sets of mother and daughter cases, sibling cases, and twin cases. The Japanese nationwide study in 2006 showed that the familial occurrence in patients aged <5 years was 2.38%, which was higher than other ages, but was not statistically different. Other autoimmune disorders, such as hyperthyroid disease, might occur also in the family.
Thymoma hardly occurs in childhood MG. The Japanese 2006 nationwide study, however, showed 3.6% in the onset <5 years, and 10.0% in the onset 5-9 years. 5 
Spontaneous remission
Spontaneous remission is frequently seen in childhood MG. However, the treatment is started immediately on diagnosis of the disease, so usually one will not count on the possibility of spontaneous remission.
Transient neonatal MG
Transient neonatal MG is a disorder seen in infants whose mothers have autoimmune MG. The circulating maternal autoantibodies cross the placenta from approximately the 16th week of gestation, and inhibit the neuromuscular transmission in the neonate. Detectable antibodies are not always present, and mothers are sometimes asymptomatic. Neonates might be asymptomatic at the beginning, but subsequently develop symptoms, such as weak cry, poor sucking, ptosis, weak facial muscles, hypotonia or respiratory insufficiency.
Diagnosis
The diagnosis of childhood MG is primarily clinical, which is the same as in adult patients. Taking precise medical history and neurological examinations are essential to make the diagnosis. Weakness of the ocular, bulbar and/or general muscles with fluctuation are the symptoms to be noted.
Diagnostic tests include the following.
Tensilon test
The Tensilon test is a test to detect if neuromuscular junction abnormality is myasthenic or cholinergic. This test is carried out at the beginning to make a diagnosis of MG, and during the course, to adjust the anticholinergic medication.
Evoked electromyography
The waning phenomena observed with repetitive stimulation with a low stimulation rate suggest the fatigability of the neuromuscular junction, and are also characteristic features in children. Evoked electromyography is important to make the diagnosis of the latent general type. Single-fiber electromyography is usually not carried out because of the technical difficulty with young children.
Anti-AChR antibody
Detecting the anti-AChR antibody is useful to make the diagnosis of MG. However, childhood MG is often seronegative, or shows low titers. The anti-AChR antibody of our 184 patients correlated with the clinical types. The ocular type was shown to be negative or low positive, the latent general type was shown to be mildly positive and the general type was moderately positive (Figs 2,3) . 13 There were tendencies that anti-AChR increase after 15 years-of-age. Some patients showed a marked increase of titers at approximately 20 years-of-age. Those patients were either the general type or the latent general type with relapses. After repeated relapses and remissions, the patients became stable with the sequela of minor ocular symptoms, such as mild strabismus or transient blepharoptosis, which are usually Tensilon non-responsive.
A nationwide study in 2006 showed that 70-90% of adult patients were positive for anti-AChR, but just 50.3% of patients with onset <5 years-of-age and 48.1% with onset 5-10 years-of-age were positive. 5 
Antibodies to clustered AChR
It was reported that among seronegative patients, antibodies to clustered AChR, being measured by sensitive cell-based assays, could be found in some of the patients. 20 This antibody was reported to be positive in prepubertal onset, ocular symptoms and generally milder cases. 21 Anti-muscle-specific receptor tyrosine kinase antibody Among patients without AChR antibodies, some show antibodies against another neuromuscular junction protein, muscle-specific receptor tyrosine kinase. However, muscle-specific receptor tyrosine kinase-positive MG is rare in children. If this occurs, the children present distinct characteristics. Antimuscle-specific receptor tyrosine kinase antibodypositive patients show a marked female predominance, and are associated with more severe symptoms, with prominent facial and bulbar weakness, and frequent respiratory crisis.
Differential diagnosis
The most important differential diagnosis of childhood MG is congenital myasthenic syndrome. Congenital myasthenic syndrome is a group of disorders with heterogeneous etiologies, usually due to genetic abnormalities involving various components of the neuromuscular junction. 15 Fluctuating ptosis or abnormal eye position needs to be differentiated. Those include mitochondrial abnormality, ophthalmoplegic migraine and congenital ptosis with upward gaze abnormality. 15 Other potential diagnoses include cranial nerve palsies, Guillain-Barr e syndrome, myopathies, botulism, Lambert-Eaton myasthenic syndrome, venoms, toxins, drug effects and hysteria. 22 
Treatments

Overall treatment strategies
The history of the treatment of childhood MG showed that before the 1940s and 1950s, approximately one-third of patients died, one-third deteriorated or remained unchanged and one-third improved. [23] [24] [25] The Mayo Clinic reported no death in pediatric patients after 1972, and Andrews reported no death of 115 pediatric patients followed for 1-44 years. Our experiences also showed no death. The aim of the treatment is complete remission without sequela. However, MG takes a chronic course, and the right treatments have to be chosen according to the course, and need to be individualized.
Therapeutic strategies for autoimmune MG consist of the following four categories: 27 1 Anticholinesterases 2 Oral steroid hormone and other immunosuppressive medications 3 Thymectomy 4 Plasma exchange and intravenous immunoglobulin infusion
Treatment of ocular type
Symptoms of childhood MG are predominantly ocular: starting with ocular symptoms, and remaining so throughout the course. The latent general type needs to be differentiated, because clinically, the latent general type mimics the ocular type, and its treatment is different from pure ocular type. Treatment of ocular MG in childhood usually starts with anticholinesterase. It is increased up to the optimal dose, and maintained at that dose. Anticholinesterase is the symptomatic treatment. Some ocular type patients achieve complete remission only with anticholinesterase. However, if there is no improvement, or the effects are insufficient, steroid treatment becomes necessary. Oral prednisolone every other day is used, and is increased gradually up to 1-1.5 mg/kg every other day. Caution is required regarding the side-effects of anticholinesterase.
Treatment of latent general type
Treatment of the latent general type follows the rules of generalized MG. Anticholinesterase medication might improve initial symptoms, but it is not possible to bring about remission, and relapses can occur. Introducing steroid treatment in the early phase can bring patients to complete remission. Oral prednisone is administrated every other day with a gradual increase to the optimal dose within a few months. Symptoms disappear with 1-1.5 mg/kg every other day or a maximum of 2 mg/kg every other day. The dose is maintained for a few months, and is tapered down gradually to 2.5-5 mg every few months. When the dose reaches 15-20 mg/day, the dose is maintained for longer, then decreased further to zero. When steroid treatment is not effective, other immunosuppressive medication; for example, tacrolimus, is recommended. The dose of tacrolimus is 0.05 mg/kg/day, and checking the blood level is helpful to adjust the dose. The maximum dose is the same as adults i.e. 3 mg/day. Most latent general patients can be brought to a symptom-free state; however, some cases of latent general cannot be brought to a symptom-free state when steroid treatment is not used properly or with an extremely high anti-AChR antibody titer. Caution is advised in regard to early exaggeration and side-effects of steroid treatment. The dose and duration of steroids needs to be individualized.
Treatment of general type
The general type MG is less frequent in children compared with adults. However, because young children do not complain, careful history taking, observation and detection of the general symptoms are essential. Administer steroids starting with a low dose, and increase up to the optimal dose within 1-2 months, the same way as latent general.
Regarding intravenous methylprednisolone treatment, there are no sufficient data on its efficacy in childhood MG. Introducing other immunosuppressive drugs is an alternative if steroid treatment fails. Thymectomy is one of the therapies for puberty, but there is no sufficient evidence regarding the effect of thymectomy on the immune system during development.
Treatment outcomes
We analyzed the results of the treatment of 136 patients whose symptoms had been stabilized. 13 The overall results showed that 22 patients (16.2%) responded to anticholinesterase, 62 patients (45.6%) responded markedly to steroid treatment, 17 patients (12.5%) responded moderately to steroid treatment (i.e. left with minimum ocular symptoms), 15 patients (11.0%) were resistant to steroid treatment, 13 patients (9.6%) had thymectomy, one patients (0.7%) had complete remission with measles infection and six patients (4.4%) went into remission without any treatment. Thus, approximately 60% responded to steroid treatment (Fig. 4) .
The effects of the treatments were distinct in each clinical type. Most of the patients with the ocular type responded to the treatments, either anticholinesterase or steroid, and there were three (16.7%) spontaneous remissions and one patient (5.6%) with remission after measles. There were no steroid-resistant patients. In the latent general type, approximately 85% responded to either anticholinesterase or steroid treatment, two (2.4%) presented with spontaneous remission, approximately 10% were resistant to steroid treatment and two patients (2.4%) required thymectomy. The general type showed that approximately 50% responded to steroid treatment, 20% were resistant to steroid treatment and 28% required thymectomy (Fig. 4) .
The duration (mean AE standard deviation) between the onset of MG and the start of steroid treatment in good responders (n = 27) was 25 AE 33 months. As to the clinical types, the ocular type (n = 3) was 58 AE 62 months, the latent general type (n = 17) was 25 AE 31 months and the general type (n = 7) was 10 AE 6 months.
The patients (n = 9) who had poor response to steroid treatment showed a longer time lag (37 AE 24 months) between onset of MG and starting steroid treatment. In the clinical types, it was 39 AE 20 months in the latent general type (n = 6) and 33 AE 36 months in the general type (n = 3).
Retrospective analysis of the total duration and amount of prednisolone showed a linear relationship for both duration and amount versus the clinical subtypes and final states of the patients; that is, no symptoms, with sequela of the symptoms and steroid resistant. There were statistical differences among the final states.
To achieve a good response, steroid treatment should be initiated within 3 years of onset of MG. This supports steroid treatment, and it is related to the clinical types. 13 They showed the parallel correlation between the clinical type and earlier initiation of steroid treatment for a final favorable outcome. Thus, steroid treatment can lead to complete remission in the majority of childhood MG patients if it is started within a certain time lag after onset. The timing of the tapering of steroid treatment is important. If it was tapered too early, it often causes relapses, so careful monitoring is mandatory.
Tacrolimus is safely used to switch from steroid treatment. In steroid-resistant patients (n = 10), tacrolimus has been used in recent years, and all patients have shown good results. 27 Clinical type and ages should be taken into consideration.
Prognosis
The course and prognosis differ according to the age of onset, clinical type and treatment chosen. Early diagnosis and appropriate treatment can bring patients to complete remission. However, there are patients who become steroid dependent, develop other autoimmune disorders and take a serious course, or relapse after many years. The introduction of these treatments and advanced respiratory support have dramatically improved the prognosis of childhood and adolescent autoimmune MG.
Human leukocyte antigen association
Human leukocyte antigens (HLA) and MG have been studied in adult-onset MG, which showed the strong association with HLA-A1, B8 and DR3 in Caucasians, but no clear associations were found in Asians. HLA were studied in 104 childhood-onset patients and 41 families with MG. 28 The frequencies of DR9 and DRw13 were increased significantly in the group with the onset before 3 years of age. As for DQ antigens, all, but one patient, with onset before 15 years of age were positive for DQw3.
The HLA of childhood-onset MG in Japan shows the specific relationship with class II antigens, DR 9/ 13 and DQ 6/9. A family study revealed diverse DR9 haplotypes. The family study showed discordance in two monozygotic twins and one dizygotic twin.
These results showed that childhood MG in Japan is genetically distinct from adults and Caucasians. The difference in the HLA frequencies in the age at onset is striking. This finding suggests that non-genetic factors are also required in developing MG. No significant differences between sexes were found, except that DRw13 frequency was slightly higher in males than in females in the group with onset <3 years-ofage, but no statistical differences were observed. HLA antigens of the latent general type were shown to be unique, which support the special underlying pathomechanism of the latent general type.
Pathophysiology
The pathophysiology of childhood autoimmune MG is basically the same as in adults, which is an antibody-mediated process, directed against the AChR in skeletal muscle. Age and sex influence the incidence of MG in childhood. Factors initiating the disease are not yet known. Childhood MG is often associated with viral infection at onset, and fluctuates through the course. The immune systems undergo marked changes and maturation throughout childhood. Different HLA antigens are linked to autoimmune MG in Japanese patients with onset before the age of 6 years compared with later onset. It is conceivable, therefore, that maturation of the immune system influences the natural history and response to therapy of childhood MG. Thus, therapeutic strategies vary with the age of onset. In addition, long-term consequences of therapies for autoimmune MG might differently affect the developing child and already developed adult.
Conclusion
Childhood MG is frequently seen in Japan and other countries in eastern Asia. It has very distinct characteristics. We should be aware of the existence of latent generalized MG patients, because they mimic the ocular type. The prognosis is good in general, sometimes showing spontaneous remission. The pathomechanism and treatment strategy of childhood MG should be vigorously investigated in the near future.
Disclosure
Conflict of interest:
The author declares no conflict of interest. Human studies: No human participants were involved in this study. Animal studies: No animals were used in this study.
